Whole-transcriptome Sequencing Identified Gene Expression Signatures Associated with Aggressive Clear Cell Renal Cell Carcinoma

Overview

Journal Genes Cancer

Specialty Oncology

Date 2019 Jan 4

PMID 30603059

Citations 8

Authors

Ken Batai

Elliot Imler

Jayce Pangilinan

Robert Bell

Aye Lwin

Elinora Price

Tijana Milinic

Amit Arora

Nathan A Ellis

Erika Bracamonte

Bruce Seligmann

Benjamin R Lee

Affiliations

Soon will be listed here.

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, yet molecular biomarkers have not been used for the prognosis of ccRCC to aide clinical decision making. This study aimed to identify genes associated with ccRCC aggressiveness and overall survival (OS). Samples of ccRCC tumor tissue were obtained from 33 patients who underwent nephrectomy. Gene expression was determined using whole-transcriptome sequencing. The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) RNA-seq data was used to test association with OS. 290 genes were differentially expressed between tumors with high and low stage, size, grade, and necrosis (SSIGN) score (≥7 . ≤3) with <0.05. Four genes, , , , and , were also over-expressed in advanced stage (III and IV) and high grade (3 and 4) ccRCC and tumor with necrosis ( <0.05). Investigation stratifying by stage found that and overexpression were significantly associated with poorer OS in the early stage (Quartile 1 vs. Quartile 4, HR = 3.87, 95% CI:1.25-11.97, = 0.02 and HR = 4.77, 95% CI:1.37-16.57, = 0.04 respectively). These genes are potential biomarkers of ccRCC aggressiveness and prognosis that direct clinical and surgical management.

Citing Articles

GCNT3 promotes the proliferation, apoptosis, invasion, and migration of breast cancer through the PI3K/AKT pathway.

Li Y, Ren Z, Wu T, Zhang N, He Z Transl Cancer Res. 2024; 13(11):6381-6393.

PMID: 39697709 PMC: 11651748. DOI: 10.21037/tcr-2024-2248.

Transcriptomic landscape based on annotated clinical features reveals PLPP2 involvement in lipid raft-mediated proliferation signature of early-stage lung adenocarcinoma.

Wang Y, Miao Z, Qin X, Yang Y, Wu S, Miao Q J Exp Clin Cancer Res. 2023; 42(1):315.

PMID: 37996944 PMC: 10666437. DOI: 10.1186/s13046-023-02877-w.

Clear cell renal cell carcinoma molecular variations in non-Hispanic White and Hispanic patients.

Batai K, Chen Y, Rheinheimer B, Arora A, Pandey R, Heimark R Cancer Med. 2023; 12(11):12792-12801.

PMID: 37081700 PMC: 10278477. DOI: 10.1002/cam4.5929.

Development of a metabolism-related signature for predicting prognosis, immune infiltration and immunotherapy response in breast cancer.

Li C, Tao Y, Chen Y, Wu Y, He Y, Yin S Am J Cancer Res. 2023; 12(12):5440-5461.

PMID: 36628282 PMC: 9827085.

Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures.

Bubak A, Mescher T, Mariani M, Frietze S, Hassell Jr J, Niemeyer C Neurol Neuroimmunol Neuroinflamm. 2021; 8(6).

PMID: 34493606 PMC: 8424492. DOI: 10.1212/NXI.0000000000001078.

References

Frank I, Blute M, Cheville J, Lohse C, Weaver A, Zincke H . An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168(6):2395-400. DOI: 10.1016/S0022-5347(05)64153-5. View

Calle E, Rodriguez C, Walker-Thurmond K, Thun M . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625-38. DOI: 10.1056/NEJMoa021423. View

Brindley D . Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem. 2004; 92(5):900-12. DOI: 10.1002/jcb.20126. View

Kosari F, Parker A, Kube D, Lohse C, Leibovich B, Blute M . Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005; 11(14):5128-39. DOI: 10.1158/1078-0432.CCR-05-0073. View

Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Sano F . A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int J Cancer. 2008; 123(5):1126-32. DOI: 10.1002/ijc.23641. View

Lane B, Li J, Zhou M, Babineau D, Faber P, Novick A . Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. J Urol. 2008; 181(2):849-60. PMC: 2706314. DOI: 10.1016/j.juro.2008.10.069. View

Chow W, Dong L, Devesa S . Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-57. PMC: 3012455. DOI: 10.1038/nrurol.2010.46. View

Brannon A, Reddy A, Seiler M, Arreola A, Moore D, Pruthi R . Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer. 2010; 1(2):152-163. PMC: 2943630. DOI: 10.1177/1947601909359929. View

Tan W, Hildebrandt M, Pu X, Huang M, Lin J, Matin S . Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol. 2011; 186(5):2071-7. PMC: 3348612. DOI: 10.1016/j.juro.2011.06.049. View

10.

Wozniak M, Le Calvez-Kelm F, Abedi-Ardekani B, Byrnes G, Durand G, Carreira C . Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States. PLoS One. 2013; 8(3):e57886. PMC: 3589490. DOI: 10.1371/journal.pone.0057886. View

11.

Chen D, Gassenmaier M, Maruschke M, Riesenberg R, Pohla H, Stief C . Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma. J Urol. 2013; 191(2):479-86. DOI: 10.1016/j.juro.2013.08.052. View

12.

Gati A, Kouidhi S, Marrakchi R, El Gaaied A, Kourda N, Derouiche A . Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict. Oncoimmunology. 2014; 3(1):e27810. PMC: 4010540. DOI: 10.4161/onci.27810. View

13.

Eckel-Passow J, Igel D, Serie D, Joseph R, Ho T, Cheville J . Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis. Urol Oncol. 2014; 33(2):68.e17-23. DOI: 10.1016/j.urolonc.2014.07.019. View

14.

Gonzalez-Vallinas M, Vargas T, Moreno-Rubio J, Molina S, Herranz J, Cejas P . Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer. Eur J Cancer. 2014; 51(1):1-8. DOI: 10.1016/j.ejca.2014.10.021. View

15.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

16.

Heymsfield S, Peterson C, Thomas D, Heo M, Schuna Jr J . Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. Obes Rev. 2015; 17(3):262-75. PMC: 4968570. DOI: 10.1111/obr.12358. View

17.

Thibodeau B, Fulton M, Fortier L, Geddes T, Pruetz B, Ahmed S . Characterization of clear cell renal cell carcinoma by gene expression profiling. Urol Oncol. 2015; 34(4):168.e1-9. DOI: 10.1016/j.urolonc.2015.11.001. View

18.

Pandey P, Sliker B, Peters H, Tuli A, Herskovitz J, Smits K . Amyloid precursor protein and amyloid precursor-like protein 2 in cancer. Oncotarget. 2016; 7(15):19430-44. PMC: 4991393. DOI: 10.18632/oncotarget.7103. View

19.

Rao C, Janakiram N, Madka V, Kumar G, Scott E, Pathuri G . Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. Cancer Res. 2016; 76(7):1965-74. DOI: 10.1158/0008-5472.CAN-15-2820. View

20.

Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E . Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep. 2016; 14(10):2476-89. PMC: 4794376. DOI: 10.1016/j.celrep.2016.02.024. View